Literature DB >> 9258817

Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics.

R Bradford1, H Koppel, G J Pilkington, D G Thomas, J L Darling.   

Abstract

Heterogeneity in drug sensitivity must, in part, account for the relative lack of success with single agent chemotherapy for glioblastoma multiforme (GBM). In order to develop in vitro model systems to investigate this, clones derived from the VM spontaneous murine astrocytoma have been characterised with regard to drug sensitivity. Six clonal cell lines have been tested for sensitivity to a panel of cytotoxic drugs using an intermediate duration 35S-methionine uptake assay. These lines have previously been extensively characterised with regard to morphological, antigenic, kinetic, tumourigenic potential in syngeneic animals and chromosomal properties and display considerable heterogeneity. The present study indicates that heterogeneity extends to sensitivity to all classes of cytotoxic drugs. The greatest difference in sensitivity between the clones was seen in response to cell cycle-specific drugs like the Vinca alkaloids (14-fold and 20-fold for vincristine (VCR) and vindesine (VIND) respectively), while the nitrosoureas, CCNU and BCNU displayed a smaller fold difference in sensitivity (4.3 and 3.6-fold difference respectively). All the clones were considerably more resistant to the adriamycin (ADM), cis-platinum (C-PLAT) and the Vinca alkaloids than the parental cell line although the difference in sensitivity between the clones and parental cell line were less marked for the nitrosoureas and procarbazine (PCB). It has also been possible to examine the relationship between drug sensitivity and the phenotypic and genotypic properties of these clonal cell lines. There is a relationship between chromosome number and sensitivity of a wide variety of cytotoxic drugs including the nitrosoureas, Vinca alkaloids, PCB, C-PLAT, BLEO but not ADR or 5-FU. Clones with small numbers of chromosomes were more resistant than clones with gross polyploidy. Similarly, sensitivity to Vinca alkaloids and ADM, but not other classes of drugs, was greatest in cells with numerous cytoplasmic processes and which did not express large amounts of cell surface fibronectin. Preliminary experiments have been conducted on reconstituting clonal mixtures of cells with different sensitivity to Vinca alkaloids and results from these studies indicate that the drug resistance phenotype is dominant, with clonal mixtures of sensitive and resistant cell adopting the sensitivity of the more resistant partner. These cell lines should prove to be useful models for examining the cell biological basis of drug resistance in glioma and may lead to the identification and exploitation of novel cellular targets in new therapies for GBM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258817     DOI: 10.1023/a:1005704223040

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  52 in total

1.  Prognostic significance of nuclear DNA content in human neuroepithelial tumors.

Authors:  M Danova; W Giaretti; F Merlo; G Mazzini; P Gaetani; E Geido; S Gentile; G Butti; A Di Vinci; A Riccardi
Journal:  Int J Cancer       Date:  1991-07-09       Impact factor: 7.396

2.  Heterogeneity of a cultured neoplastic glial line. Establishment and characterisation of six clones.

Authors:  H Koppel; J M Martin; G J Pilkington; P L Lantos
Journal:  J Neurol Sci       Date:  1986-12       Impact factor: 3.181

3.  DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells.

Authors:  L C Erickson; G Laurent; N A Sharkey; K W Kohn
Journal:  Nature       Date:  1980-12-25       Impact factor: 49.962

Review 4.  The implications of tumor heterogeneity for studies on the biology of cancer metastasis.

Authors:  I R Hart; I J Fidler
Journal:  Biochim Biophys Acta       Date:  1981-08-31

5.  Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate.

Authors:  B E Miller; F R Miller; G H Heppner
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

Review 6.  Amplified genes in human gliomas.

Authors:  V P Collins
Journal:  Semin Cancer Biol       Date:  1993-02       Impact factor: 15.707

7.  Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas.

Authors:  M Hermanson; K Funa; J Koopmann; D Maintz; A Waha; B Westermark; C H Heldin; O D Wiestler; D N Louis; A von Deimling; M Nistér
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

8.  Prognosis in malignant glioma: a retrospective study of biopsy specimens by flow cytometry.

Authors:  O Jimenez; A Timms; P Quirke; J E McLaughlin
Journal:  Neuropathol Appl Neurobiol       Date:  1989 Jul-Aug       Impact factor: 8.090

Review 9.  DNA repair: relationship to drug and radiation resistance, metastasis and growth factors.

Authors:  A L Harris
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1985-11

10.  Relationships among tenascin expression, DNA ploidy patterns, and multidrug resistance gene product (P-glycoprotein) in human colon carcinoma.

Authors:  I Sugawara; J Hirakoshi; M Kusakabe; A Masunaga; S Itoyama; T Sakakura
Journal:  Jpn J Cancer Res       Date:  1993-07
View more
  2 in total

1.  Understanding the role of the tumour vasculature in the transport of drugs to solid cancer tumours.

Authors:  N S Wijeratne; K A Hoo
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

2.  Gene expression, proteome and calcium signaling alterations in immortalized hippocampal astrocytes from an Alzheimer's disease mouse model.

Authors:  Francesca Rocchio; Laura Tapella; Marcello Manfredi; Mariangela Chisari; Francesca Ronco; Federico Alessandro Ruffinatti; Eleonora Conte; Pier Luigi Canonico; Maria Angela Sortino; Mariagrazia Grilli; Emilio Marengo; Armando A Genazzani; Dmitry Lim
Journal:  Cell Death Dis       Date:  2019-01-10       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.